




Find more of what you can't see.

IDEXX Cancer Dx™ Panel clinical reference guide.

IDEXX



Canine cancer is incredibly common.





**Approximately 1 in 4 dogs in the U.S. will be
diagnosed with cancer in their lifetime.¹**



Cancer is the leading cause of death in adult dogs.²

For many cancers, patients aren't diagnosed until the later stages and clinical signs are present. These types of situations often lead to poorer outcomes and lower survival rates.



Lymphoma and mast cell tumors are two of the most common cancers encountered in dogs,¹ comprising up to 1/3 of canine cancer cases.³

Cancer risk in dogs is greatly shaped by two factors: age and breed.

Studies show that the risk of cancer increases with age.⁴



The average age of dogs diagnosed with cancer.⁴

Cancer screenings are recommended for all dogs age 7 or older as well as dogs age 4 and older from these breeds:

- | | |
|-------------------------|------------------------|
| + Beagle | + Irish wolfhound |
| + Bernese mountain dog | + Labrador retriever |
| + Boston terrier | + Miniature schnauzer |
| + Boxer | + Pembroke Welsh corgi |
| + Bullmastiff | + Rhodesian ridgeback |
| + Chinese pug | + Rottweiler |
| + Doberman pinscher | + Scottish deerhound |
| + English bulldog | + Scottish terrier |
| + Flat-coated retriever | + Shar-pei |
| + French bulldog | + Siberian husky |
| + German shepherd | + Weimaraner |
| + Golden retriever | |



Decrease the possibility of illness going undetected by expanding your preventive care offering.

Preventive care allows veterinarians to catch health issues earlier and help pets live healthy lives. With comprehensive diagnostics from IDEXX, you can get deeper medical insight into your patients' health. But even with comprehensive diagnostics, such as a CBC, chemistry profile, and urinalysis, cancer can still go undetected.

When it comes to cancer detection, the diagnosis often comes too late in the game. Until now, there has been no easy, affordable screening panel that could be integrated into a wellness offering.



Accurate, affordable detection of lymphoma and mast cell tumors.

Help detect cancer as an additional component of your IDEXX Preventive Care diagnostics for at-risk dogs.*

What is the IDEXX Cancer Dx Panel?

Finding cancer early is only the first step. Knowing what to do next is what matters most. The expanded IDEXX Cancer Dx™ Panel now helps detect mast cell tumors in addition to lymphoma, giving you broader insight into two of the most common canine cancers.³ More than expanded detection, you get clinically meaningful information that helps you move confidently.

Confidence you can act on.

The IDEXX Cancer Dx Panel detects canine lymphoma with 79% sensitivity and 99% specificity. For mast cell tumor, the panel's MCT assay offers 99% specificity, with sensitivity of 22–41%, purposefully weighted toward catching the high-grade, clinically significant tumors where early detection matters most.

*At-risk dogs include all dogs $\geq$ 7 years old and high-risk breeds $\geq$ 4 years old.



Specimen requirements


2 mL of serum and 1 mL of EDTA whole blood when run as a standalone, add-on, or in a profile. When run in a profile with chemistry and CBC, a separate pair of tubes is not required. The IDEXX Cancer Dx Panel is run using a portion of the 2 mL serum/1 mL whole blood specimen required for standard biochemistry and hematology testing.

Why is cancer screening important?


There is a shifting focus in oncology to early detection of cancers to provide more time for planning and a larger scope of opportunities to treat the disease. Designed to identify lymphoma and mast cell tumors, the IDEXX Cancer Dx Panel helps support earlier investigation and intervention.



IDEXX Cancer Dx™ Panel: Interpreting results for apparently healthy dogs




IDEXX Cancer Dx™ Panel: Interpreting lymphoma results for dogs with suspicion of disease



IDEXX Cancer Dx™ Panel: Interpreting mast cell tumor (MCT) results for dogs with suspicion of disease

The IDEXX Cancer Dx Panel is intended for use as a screening test in apparently healthy, at-risk dogs.*
The algorithm presented here applies to dogs in which MCT is already suspected, which is outside the panel's current recommended use.



Detection rates of mast cell tumors vary by clinical aggressiveness. Positive results are more common in high-grade cutaneous, biologically aggressive subcutaneous, and visceral tumors. The IDEXX Cancer Dx Panel has limited detection of low-grade cutaneous and subcutaneous tumors with low-grade features.

Get the support you need when there's no time to waste.

Diagnosing cancer can be difficult, but the expanded cancer offerings at IDEXX Reference Laboratories can help.

The tests and services offered by IDEXX Reference Laboratories can help identify cancer, understand personalized genetic markers, and determine diagnostics for therapy management and monitoring.



Personalized guidance from diagnosis to treatment.

Get the support that you need from the largest global network of veterinary pathologists and medical consultants at IDEXX Reference Laboratories:

- + Clinical support for routine and complex pathology cases
- + Easy access to your case's pathologist by phone and email, and consistency with a dedicated pathologist from start to finish
- + Education on when and which diagnostics are best for personalized medicine
- + Evaluation of surgical margins
- + Internal case review and collaboration
- + Comments about biological behavior and etiology
- + Cytology interpretation from a board-certified clinical pathologist in 2 hours or less, 24/7/365, with IDEXX Digital Cytology™*

Expand your pathology insights with VetConnect PLUS.

Everything you need for faster, effective clinical decisions all in one place:

- + High-resolution digital images of your cytology and biopsy cases included at no charge, exclusively with VetConnect™ PLUS
- + Access to each patient's comprehensive diagnostic information (CBC, chemistry profile, urinalysis, digital radiography) in one place for a holistic view in VetConnect PLUS



Our comprehensive diagnostic portfolio gives you clarity.

The test and service menu gives you the answers you need, when you need them:

Cancer identification

- + IDEXX Cancer Dx™ Panel
- + Priority Cytology
- + Priority Biopsy
- + Bone Marrow Cytology and Biopsy with Microscopic Description

Cancer characterization

- + Mast Cell Tumor Prognostic Panel
- + Immunocytochemical Staining, as recommended by pathology
- + Immunohistochemistry, as recommended by pathology
- + Lymphoma PCR, includes the PARR assay for clonality

Chemotherapy patient monitoring

- + Cancer Baseline Profile with Urinalysis
- + Cancer Baseline Profile and SediVue Dx™ Urinalysis[†]
- + Chemotherapy Recheck Profile
- + Chemotherapy Recheck Profile with Urinalysis
- + Cancer Dx lymphoma testing

[†]Urinalysis is performed on the SediVue Dx™ Urine Sediment Analyzer.



References

1. What are the most common types of cancers in dogs? How many dogs typically get cancer? Veterinary Cancer Society; 2021. Accessed March 21, 2025. www.vetcancersociety.org/pet-owners/faqs
2. Fleming JM, Creevy KE, Promislow DE. Mortality in North American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death. *J Vet Intern Med.* 2011;25(2):187–198. doi:10.1111/j.1939-1676.2011.0695.x
3. Vail DM, Pinkerton M, Young KM. Hematopoietic tumors. In: Vail DM, Thamm DH, Liptak JM, eds. *Withrow & MacEwen's Small Animal Clinical Oncology*. 6th ed. Saunders; 2020:688–772. doi:10.1016/B978-0-323-59496-7.00033-5
4. Rafalko JM, Kruglyak KM, McCleary-Wheeler AL, et al. Age at cancer diagnosis by breed, weight, sex, and cancer type in a cohort of more than 3,000 dogs: determining the optimal age to initiate cancer screening in canine patients. *PLoS One.* 2023;18(2):e0280795. doi:10.1371/journal.pone.0280795
5. Tadesse GF, Tegaw EM, Abdisa EK. Diagnostic performance of mammography and ultrasound in breast cancer: a systematic review and meta-analysis. *J Ultrasound.* 2023;26(2):355–367. doi:10.1007/s40477-022-00755-3

IDEXX

IDEXX
One IDEXX Drive
Westbrook, ME 04092
United States

> idexx.com/cancerdx

© 2026 IDEXX Laboratories, Inc. All rights reserved. • 09-2691876-03
All trademarks are owned by IDEXX Laboratories, Inc. or its affiliates
in the United States and/or other countries. The IDEXX Privacy Policy
is available at idexx.com.